FDA Approves New Targeted Therapy for Advanced Prostate Cancer

The FDA has granted approval for a new combination therapy, Truqap with abiraterone and prednisone, for adults with metastatic prostate cancer that is PTEN-deficient. This marks a significant advancement as the first targeted treatment for this specific patient group, allowing for biomarker-guided therapy earlier in the disease progression. The approval is based on positive results from the CAPItello-281 clinical trial.